Search

Search Constraints

You searched for: Author/Creator Eek, R.

Search Results

1. ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL). (12th June 2019)

2. SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB‐3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). (June 2017)

3. PO-44: Risk assessment model potency to detect patients most likely to benefit from thromboprophylaxis: an application of the TARGET- TP score. Issue 213 (May 2022)

4. OC-15: Targeted thromboprophylaxis in ambulatory patients receiving anticancer therapies for lung or gastrointestinal cancers (TARGET-TP); a randomized trial. Issue 213 (May 2022)

5. ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY. (17th June 2021)

6. P720: PROACTIVE DASATINIB DOSE REDUCTION IN THE ALLG CML 12 DIRECT STUDY BASED ON TROUGH LEVELS MINIMISE TOXICITY AND PRESERVE EFFICACY. (23rd June 2022)

7. P1131: POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERATIVE VARIANTS OF MANTLE CELL LYMPHOMA TREATED WITH ACALABRUTINIB. (23rd June 2022)

9. 13 THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL. (April 2015)